Sugi Predict

Sugi Predict / Compounds / SCHEMBL940075

SCHEMBL940075

SCHEMBL940075

CC(C)COc1ccc(Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.54
▸ KDM4E B2RXH2 6/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ HPGD P15428 4/20 0.47
▸ POLB P06746 2/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ ALDH1A1 P00352 6/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ GAA P10253 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15871072 0.89 KDM4E (0.48) MAPTKDM4EMAPK1TDP1HPGD
SCHEMBL123415 0.88 MAPT (0.55) MAPTKDM4ETDP1HPGDPOLB
SCHEMBL16622968 0.83 MAPT (0.51) MAPTKDM4EMAPK1TDP1HPGD
SCHEMBL20912223 0.83 LMNA (0.64) MAPTKDM4EMAPK1TDP1HPGD
SCHEMBL92183 0.83 LMNA (0.64) MAPTKDM4EMAPK1TDP1HPGD
SCHEMBL23474864 0.83 MAPT (0.51) MAPTKDM4EMAPK1TDP1HPGD
SCHEMBL18990350 0.83 LMNA (0.64) MAPTKDM4EMAPK1TDP1HPGD
SCHEMBL20851318 0.81 MAPT (0.58) MAPTKDM4EHPGDPOLBXBP1
SCHEMBL9142460 0.81 MAPT (0.50) MAPTKDM4EMAPK1TDP1HPGD
SCHEMBL9142467 0.81 MAPT (0.50) MAPTKDM4EMAPK1TDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106008375-A Preparation method of novel liquid crystal display enhancing luminescence agent 昆山海卓生物医药有限公司 2016-10-12 — — CN claimed
WO-2020254558-A1 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2020-12-24 — — WO disclosed
US-20200339544-A1 Epidermal growth factor receptor inhibitors JOINT STOCK COMPANY "BIOCAD" (RU) 2020-10-29 — — US disclosed
EP-3693365-A1 EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS Joint Stock Company "Biocad" (RU) 2020-08-12 — — EP disclosed
US-10550080-B2 Acyl sulfonamide NaV1.7 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-02-04 — — US disclosed
US-10550080-B2 Acyl sulfonamide NaV1.7 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-02-04 — — US disclosed
US-20190119209-A1 ACYL SULFONAMIDE NaV1.7 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2019-04-25 — — US disclosed
US-20190119209-A1 ACYL SULFONAMIDE NaV1.7 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2019-04-25 — — US disclosed
WO-2019070167-A1 EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS ЗАКРЫТОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО "БИОКАД" 2019-04-11 — — WO disclosed
US-9879034-B2 Near-infrared absorption composition, cured film, near-infrared cut filter, solid-state imaging device, infrared sensor, and compound FUJIFILM CORPORATION (JP) 2018-01-30 — — US disclosed
EP-1140896-A1 BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 Takeda Chemical Industries, Ltd. (JP) 2001-10-10 — — EP disclosed
CN-1066441-C Phenyl sulfonamide endothelin antagonists SQUIBB & SONS INC (US) 2001-05-30 — — CN disclosed
US-6235771-B1 AIDS THERPAY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 — — US disclosed
US-6107320-A Phenyl sulfonamide endothelin antagonists BRISTOL-MYERS SQUIBB CO. (US) 2000-08-22 — — US disclosed
WO-2000037455-A1 BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-06-29 — — WO disclosed
EP-0569193-B1 N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists SQUIBB & SONS INC (US) 1997-02-26 — — EP disclosed
US-5514696-A Phenyl sulfonamide endothelin antagonists BRISTOL-MYERS SQUIBB CO. (US) 1996-05-07 — — US disclosed
CN-1084515-A Phenyl sulfamoyl endothelium (endothelin) antagonistic SQUIBB & SONS INC (US) 1994-03-30 — — CN disclosed
EP-0569193-A1 N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists E.R. SQUIBB & SONS, INC. (US) 1993-11-10 — — EP disclosed
US-4861880-A 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1989-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550080-B2 Acyl sulfonamide NaV1.7 inhibitors SCN7A, SCN1A, SCN8A MAPT 2990/4885KDM4E 1622/4885MAPK1 2276/4885
US-20200339544-A1 Epidermal growth factor receptor inhibitors EGFR, ERBB2, ERBB3 MAPT 2473/4885KDM4E 4716/4885MAPK1 229/4885
US-20190119209-A1 ACYL SULFONAMIDE NaV1.7 INHIBITORS SCN7A, SCN1A, SCN8A MAPT 2990/4885KDM4E 1622/4885MAPK1 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.